San Francisco, CA – April 14, 2025 – VeriSIM Life, a leading innovator in artificial intelligence (AI) for drug development, is proud to announce that it has been honored with the "Best AI-Driven Drug Development Engine 2025 - USA" award at the prestigious Global Health & Pharma (GHP) Biotechnology & Lifesciences Awards.
The GHP Biotechnology & Lifesciences Awards recognize and celebrate the outstanding achievements and contributions of organizations and individuals in the biotechnology and life sciences sectors. These awards aim to highlight the innovative solutions and advancements that are addressing global health challenges and driving the industry forward.
VeriSIM Life's award-winning AI-driven drug development engine, BIOiSIMⓇ, has revolutionized the way drugs are discovered and developed. By leveraging advanced AI algorithms and machine learning, BIOiSIM accelerates the drug development process, reduces costs, and improves the accuracy of predicting drug efficacy and safety. This groundbreaking technology has the potential to bring life-saving treatments to patients faster and more efficiently.
"We are thrilled to receive this recognition from GHP," said Dr. Varshney, CEO of VeriSIM Life. "Our team is dedicated to pushing the boundaries of what is possible in drug development, and this award is a testament to our commitment to innovation and excellence. We are grateful to GHP for this honor and look forward to continuing our mission to transform the drug development landscape."
The GHP Biotechnology & Lifesciences Awards are organized by Global Health & Pharma Magazine, a leading publication that covers the latest developments and trends in the healthcare and pharmaceutical industries. The awards are highly competitive, with a rigorous evaluation process that includes nominations, shortlisting, and final selection by a panel of industry experts.
About VeriSIM Life
VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by significantly reducing the time and money it takes to bring a drug to market. BIOiSIM® is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. The platform predicts the likelihood of a candidate's success in clinical trials early in the preclinical stage, while reducing unnecessary experimentation and better informing key program decisions. For more information, visit www.verisimlife.com.
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
